Company news
Allogene Therapeutics, Inc. (NASDAQ:ALLO) news
Every Allogene Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 4, 2026
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) a...
July 29, 2026
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remiss...
July 15, 2026
Allogene Therapeutics Announces Planned CEO Succession
May 28, 2026
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
May 13, 2026
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
April 21, 2026
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
April 20, 2026
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
April 16, 2026
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Tar...
April 15, 2026
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
April 14, 2026
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedl...
April 13, 2026
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
April 13, 2026
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (...
April 10, 2026
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
March 12, 2026
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
March 12, 2026
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
March 2, 2026
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
February 5, 2026
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
January 8, 2026
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
December 15, 2025
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
November 6, 2025
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
November 3, 2025
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
October 30, 2025
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
August 27, 2025
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
August 13, 2025
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
August 6, 2025
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for C...
August 1, 2025
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cel...
June 1, 2025
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Po...
May 22, 2025
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
May 13, 2025
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
May 6, 2025
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Pos...
April 23, 2025
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, f...
April 7, 2025
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
March 13, 2025
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
March 3, 2025
Allogene Therapeutics Announces Participation in March Investor Conference
February 26, 2025
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Acr...
February 25, 2025
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtage...
February 13, 2025
Allogene Therapeutics Announces Participation in February Investor Conferences
February 4, 2025
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
January 29, 2025
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
January 28, 2025
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
December 12, 2024
Allogene Therapeutics Announces Participation in December Investor Conferences
November 19, 2024
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease ...
November 18, 2024
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advance...
November 7, 2024
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
November 7, 2024
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive...
November 5, 2024
Allogene Therapeutics Announces Participation in November Investor Conferences
November 4, 2024
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
October 30, 2024